cancer in the lung
POPULARITY
Categories
To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.
Early detection of lung cancer can save lives. In this essential episode, two-time survivor and LCFA co-founder David Sturges shares how screening helped him beat lung cancer—twice. Joined by Dr. Denise Aberle and LCFA-funded researcher Dr. Kellie Smith, this episode dives into why lung cancer is often diagnosed late, what new screening methods can do to change that, and what the future of early treatment might look like. Guests David Sturges, Lung Cancer Survivor & LCFA Co-founder Dr. Denise Aberle, Thoracic Radiologist, UCLA Medical Center Kellie Smith, Ph.D., Assistant Professor of Oncology, Johns Hopkins University & LCFA Early Career Researcher Show Notes | Transcript
In this episode of the Cancer Assist Podcast, Dr. Bill Evans sits down with Dr. Peter Ellis, medical oncologist at the Juravinski Cancer Centre, to talk about the incredible changes in lung cancer care. Once considered one of the most hopeless diagnoses, lung cancer treatment has drastically changed, with targeted therapies, immunotherapy, and personalized care offering patients more options and longer lives than ever before. Dr. Ellis shares what patients need to know about diagnosis, treatment choices, and why there's real reason to feel hopeful.----DisclaimerThe Cancer Assist Show is hosted by Dr. Bill Evans, MD, FRCP, Past President of the Juravinski Hospital and Cancer Centre at HHS. Brought to you by the Cancer Assistance Program—an organization lending support to cancer patients and families of those affected by cancer. --- The Cancer Assist Show and its content represent the opinions of Dr. Bill Evans and guests to the podcast. Any views and opinions expressed by Dr. Bill Evans and guests are their own and do not represent those of their places of work. The content of The Cancer Assist Show is provided for informational, educational and entertainment purposes only, and is not intended as professional medical, legal or any other advice, or as a substitute or replacement for any such advice. The Cancer Assist Program, Dr. Bill Evans and guests make no representations or warranties with respect to the accuracy or validity of any information or content offered or provided by The Cancer Assist Show. For any medical needs or concerns, please consult a qualified medical professional. No part of The Cancer Assist Show or its content is intended to establish a doctor-patient or any other professional relationship. This podcast is owned and produced by the Cancer Assistance Program.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC has reinstated around 460 employees who were previously fired, with the rehired staff working on viral disease prevention efforts and sexual health testing labs. This comes amid protests and shake-ups at the agency, including the overhaul of the vaccine advisory committee. Experts are concerned about newly appointed members, some of whom are known anti-vaxxers, potentially relitigating recommendations. Sen. Bill Cassidy is being urged to step up in response to these concerns.In other news, NuVation has received FDA approval for its oral lung cancer drug, Biontech has acquired CureVac in a $1.25 billion all-stock deal, and RFK Jr. has named new CDC vaccine advisors following a "clean sweep." Additionally, InVitro Cell Research is focused on discovering interventions to slow aging and prevent age-related diseases and is hiring scientists. The newsletter also includes information on layoffs at Genentech and Vertex.RFK Jr. has named eight new members to the CDC vaccine committee, replacing the 17 members he removed earlier in the week. The new choices seem to align with Kennedy's anti-vaccine views, causing concern among analysts. The HHS secretary's decision to appoint these scientists has raised questions about the committee's future direction.
In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy. Baldwin reflects on national screening programmes, groundbreaking trials, and how AI, big data, and evidence-based guidelines are reshaping lung cancer care. Timestamps: 00:00 – Introduction 03:17 – Key takeaways from the UKLS trial 11:10 – Boosting participation in screening studies 17:04 – The Targeted Lung Health Check programme 23:30 – Understanding large datasets in lung cancer epidemiology 32:44 – AI and big data in lung cancer imaging 41:43 – Shaping national guidelines 47:47 – Are we doing enough to prevent lung cancer? 53:06 – Baldwin's three wishes for healthcare
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with CTSNet JANS Editor Dr. Mateo Marin-Cuartas, a cardiac surgeon in the University Department of Cardiac Surgery at the Leipzig Heart Center, Germany, about surgical aortic valve replacement (SAVR) vs transcatheter aortic valve replacement (TAVR). Chapters 00:00 Intro 00:57 Dr. Marin-Cuartas Feature 02:28 SHURUI Robot Feasability 05:09 Touching as Diagnostic Test 09:06 Removal of Rib Stab Hardware 13:00 Resectable EGFR-Positive NSCLC 16:12 On-Pump Beating Heart MVR 17:56 Post-Infarction Myocardial Rupture 19:52 Head-First Graft Technique 22:18 SAVR vs TAVR, Dr. Marin-Cuartas 46:44 Upcoming Events 47:52 Closing They discuss SAVR and TAVR guidelines, the suitability of SAVR vs TAVR for patients aged 65-75, and mechanical heart valves. They also explore surgery after TAVR, TAVR after TAVR, and the future of addressing aortic valve stenosis. Joel also highlights recent JANS articles on the safety and feasibility of novel single-port robotic-assisted lobectomy/segmentectomy for lung cancer, touching (proximity) as a companion diagnostic test, long-term outcomes after removal of rib stabilization hardware in patients with blunt chest trauma, and advancing the needle on the management of resectable EGFR-positive NSCLC. In addition, Joel explores an on-pump beating heart mitral valve repair through right anterior minithoracotomy, post-infarction myocardial rupture treated with surgical repair and graded mechanical support, and a head-first graft technique in aortic arch replacement. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned 1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer 2.) Touching (Proximity) as a Companion Diagnostic Test 3.) Long-Term Outcomes After Removal of Rib Stabilization Hardware in Patients With Blunt Chest Trauma 4.) Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer? CTSNET Content Mentioned 1.) On-Pump Beating Heart Mitral Valve Repair Through Right Anterior Mini Thoracotomy 2.) Drain, Patch, Unload: Post-Infarction Myocardial Rupture Treated With Surgical Repair and Graded Mechanical Support 3.) Head-First Graft Technique in Aortic Arch Replacement Other Items Mentioned 1.) Career Center 2.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jaclyn LoPiccolo, MD, Ph.D., Pasi Janne, MD, Ph.D., Dana Farber Cancer Institute and Jill Feldman, EGFR Resisters Hildy opens with a powerful anecdote about an early Upstage Lung Cancer Board member whose mother, grandmother, and aunt all had lung cancer. She endured months of allergy and antibiotic treatments … Continue reading ALL IN THE FAMILY Is Lung Cancer Inherited? →
Drs. Scott and Liu discuss the safety of treatments for HER2-mutant lung cancer, including key toxicities, management strategies, and how prior therapies might affect treatment decisions.
Meet Tara Diehl and Dr. Katie Berlin and soak in hope and love as they discuss the inspiring story of Dunbar, Tara's 12-year-old dog diagnosed with primary undifferentiated pulmonary carcinoma. From the initial harrowing diagnosis to numerous treatments, including surgery, chemotherapy, and the promising effects of Palladia, Dunbar's story is a testament to hope, resilience, and the power of a dedicated dog mom … and dog insurance! The discussion highlights the importance of pet insurance, holistic care approaches, and the invaluable bond between pets, their owners, and veterinary teams. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Links: Dog Cancer Survival Guide - https://dogcancerbook.com/ Apocaps – https://apocaps.com/ Chapters: 00:00 Living in the Moment: Dunbar's Journey Begins 01:03 The Diagnosis: A Vet Tech's Worst Fear 03:18 Dunbar's Personality Shines Through 06:19 The Battle with Cancer: Treatment and Hope 08:52 Insurance and Financial Relief 14:04 A Comprehensive Approach: Supplements and Alternative Therapies 17:16 Dunbar's Resilience and Joy 18:09 Dog Cancer Resources and Support 18:38 The Impact of Attitude on Treatment 19:10 Dunbar's Medical Journey 23:57 Dunbar's Miraculous Recovery 25:26 Dunbar's Current Life and Activities 26:40 The Emotional Bond with Veterinary Teams 29:47 Final Thoughts and Encouragement 33:55 Closing Remarks and Resources Get to know Dr. Katie Berlin: https://www.dogcancer.com/people/katie-berlin-dvm/ Get to know Tara Diehl: https://www.dogcancer.com/people/tara-diehl/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices
BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.” In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis and the Richard L. Roudebush Veterans Affairs Medical Center, researchers investigated how cigarette smoke and reduced DNA repair capacity contribute together to the development of lung cancer. They found that when a critical DNA repair protein called XPC is decreased and lung cells are exposed to cigarette smoke, the combination causes extensive damage and significantly increases cancer risk. Non-small cell lung cancer (NSCLC) develops through both genetic and environmental factors. This study focused on how cigarette smoke affects the body's natural ability to repair DNA. The researchers studied the role of XPC, a protein essential for recognizing and repairing harmful DNA changes caused by tobacco smoke. They found that low levels of XPC — commonly seen in lung cancer patients — made lung cells less capable of repairing DNA. This made the cells unstable and more likely to become cancerous. These changes were most pronounced in normal lung cells, suggesting that the earliest stages of disease occur before cancer is even detected. The findings support a “double hit” model, where both cigarette smoke and reduced DNA repair work together to drive cancer development. In laboratory experiments, normal lung cells with low XPC levels showed more damage and cell death after cigarette smoke exposure. By contrast, lung cancer cells were more resistant to smoke damage, even when XPC was low, indicating that critical changes had likely occurred earlier in the disease process. “Our study suggests that cigarette smoke exposure leads to decreased XPC mRNA expression, exacerbates total and oxidative DNA damage, hinders NER, and may contribute to lung cancer development.” The study also showed that DNA repair ability declined significantly in healthy cells after smoke exposure, but this effect was not seen in cancer cells. In addition, the researchers confirmed that XPC gene activity was lower in actual lung tumor tissue compared to nearby healthy lung tissue. This pattern was consistent across both adenocarcinoma and squamous cell carcinoma, the two main types of NSCLC. These results add to our understanding of how lung cancer begins at the molecular level. By showing how cigarette smoke and reduced DNA repair combine to create genetic instability, the research points toward new strategies for prevention. A better understanding of XPC's role could help identify high-risk individuals and inform future efforts to stop lung cancer before it begins. DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book. Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer. On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited. While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results. And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this. Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas. On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes. Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program. In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system. In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense. So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers. We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer. We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost. In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer. So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future. A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology. We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode. Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Nathan Pennell @n8pennell @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Nate Pennell: Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer. Join us as we dive into five key studies that could change clinical practice: 1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer. 2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes. 3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies. 4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates. 5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights! #OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast
A pretty shhhhtty death this week!Episode notes:Brooklyn Nine-Nine' Andre Braugher Died of Lung Cancer, His Publicist SaysMatthew Perry wrote in his memoir that ketamine, the drug that led to his death, had his 'name written all over it'Rudy Giuliani is ordered to pay over $148 million to 2 Georgia election workers for defamationChinese mourners use AI to digitally resurrect the deadMarine Biologists Recently Spotted A Dolphin With Human-Like ‘Thumbs'
Stephen V. Liu, MD and Susan C. Scott, MD discuss advances in treating HER2-mutant lung cancer. Until recently, treatments for HER2-mutant lung cancer primarily involved chemotherapy, immunotherapy, and HER2-targeted therapies, with mixed results. Now, the treatment landscape of HER2-mutant lung cancer is changing.
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning recaps the 33rd European Society of Thoracic Surgeons (ESTS) annual meeting in Budapest. Chapters 00:00 Intro 01:30 ESTS 2025 Conference 09:11 SHURUI Robot Study 10:04 Willard A. Fry 12:44 Transplant Recipient Pregnancy Outcomes 15:25 Low-Flow, Low-Gradient Aortic Stenosis 17:12 Warm Ischemic Intervals Effect 19:16 Extracorp Circulation vs Conventional 23:23 Femoral Cannulation for CPB Min Invasive 24:25 Valve Sparing Aortic Root Replacement 25:27 Valve Surgery Podcast w Michael Mack 27:21 Upcoming Events 27:54 Closing He discusses the key themes and takeaways from the event, the SHURUI single-port robotic system, the hands-on experience with the da Vinci Single-Port system led by Dr. Tom Routledge, and the extraordinary guest lecture from Ernő Rubik, the inventor of the Rubik's cube. Joel also highlights various presentations from the meeting, including “Does the Fissureless Technique Really Reduce Air Leak? Results of the Prospective Randomized Study Fissureless Versus Fissurefirst (3F Trial)” by Tom Routledge, “Tour D'Horizon About Potential Newcomings in the 10th Edition” by Valerie Rusch, and much more. Additionally, he pays tribute to Willard A. Fry and his significant accomplishments. Joel also highlights recent JANS articles on pregnancy outcomes in 53 female lung transplant recipients, outcomes of surgical versus transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis, the effect of warm ischemic intervals on primary graft dysfunction in normothermic regional perfusion for donation after circulatory death heart transplant, and minimal invasive extracorporeal circulation versus conventional cardiopulmonary bypass in cardiac surgery. In addition, Joel explores femoral cannulation for CPB during minimally invasive cardiac surgery, a presentation from the Society for Cardiothoracic Surgery in Great Britain and Ireland annual meeting on “Valve Sparing Aortic Root Replacement—Tips and Tricks,” and the one-year anniversary episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with cardiothoracic surgery pioneer Dr. Michael Mack on the future of valve surgery. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned 1.) Pregnancy Outcomes in 53 Female Lung Transplant Recipients 2.) Outcomes of Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis 3.) The Effect of Warm Ischemic Intervals on Primary Graft Dysfunction in Normothermic Regional Perfusion for Donation After Circulatory Death Heart Transplant 4.) Minimal Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery: A Contemporary Systematic Review and Meta-Analysis CTSNET Content Mentioned 1.) Femoral Cannulation for CPB During Minimally Invasive Cardiac Surgery 2.) SCTS 2025 | Valve Sparing Aortic Root Replacement—Tips and Tricks 3.) The Atrium: The Future of Valve Surgery Other Items Mentioned 1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer 2.) A Eulogy for Willard A. Fry 3.) 2025 SCTS Annual Meeting Videos 4.) The Atrium—All Episodes 5.) Career Center 6.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche and Jazz Pharmaceuticals presented data at ASCO showing that their drug combination improved survival in a phase III lung cancer trial, with analysts noting a strong treatment effect. Jazz has filed for FDA approval for the combination, which could provide an alternative to monotherapy treatments from Roche and AstraZeneca. Trump's tariffs could potentially endanger the rare disease space, according to industry experts. Other news includes Kymera's success with a protein degrader candidate, Amgen's IMDelltra boosting survival in small cell lung cancer, and concerns about the impact of FDA guidelines on nitrosamine testing. BioAgilytix will be at BIO International to discuss their drug production capabilities. Other news includes Kura's new data in acute myeloid leukemia, Keros' layoffs, Regeneron's investment in a Chinese obesity drug, and Sanofi's acquisition of Blueprint to expand their rare disease portfolio. Upcoming events include webinars on AI in life science R&D and the crisis facing the pharma industry. Job opportunities in clinical data management, regulatory affairs, and scientific roles are also highlighted.
Imagine being told you only have 12 months to live. What would you do with your time? Today on Your Money, Your Wealth podcast number 532, Big Al Clopine, CPA and Executive Producer Andi Last are thrilled to welcome Jonathan Clements back for his fourth appearance. For thirty years, Jonathan has been known for his personal finance writing: in his column “Getting Going,” which appeared in the Wall Street Journal over 1,000 times starting in 1994, on his website HumbleDollar.com, and in his many acclaimed books. About a year ago, Jonathan Clements was diagnosed with a rare form of lung cancer and was told he had about a year to live. Today we're celebrating the fact that he is still here with us, and we're inspired by his decision to use his precious time to launch The Jonathan Clements Getting Going on Savings Initiative. Watch or listen to find out how you can get a free Kindle copy of Jonathan's new book, and how you can help Jonathan pay it forward for the next generation. Free financial resources & episode transcript: https://bit.ly/ymyw-532 The first 100 people to email us will receive a free Kindle copy of The Best of Jonathan Clements: Classic Columns on Money and Life WATCH Retirement Sabotage! 12 Post-Retirement Money Mistakes to Avoid on YMYW TV ASK Joe & Big Al for your Retirement Spitball Analysis SCHEDULE your Free Financial Assessment SUBSCRIBE to YMYW on YouTube DOWNLOAD more free guides READ financial blogs WATCH educational videos SUBSCRIBE to the YMYW Newsletter Timestamps: 00:00 - Intro: This Week on the YMYW Podcast 02:53 - Jonathan Clements' Getting Going on Savings Initiative 05:23 - $1,000 Roth IRA Contributions and Personal Finance Education for Young Adults 07:55 - Exponential Growth: The Sooner You Save, The Better 09:44 - Research Study Will Measure Impact on Young Savers 11:56 - Financial Education is Important 14:05 - The John C. Bogle Center for Financial Literacy 14:38 - The First 100 People to Email Us Receive a Free Copy of The Best of Jonathan Clements: Classic Columns on Money and Life 15:45 - How Does a Healthy 62-Year-Old Non-Smoker End Up Living With Stage IV Lung Cancer? The EGFR Exon 20 Insertion Mutation 18:52 - HumbleDollar.com, The Jonathan Clements Getting Going on Savings Initiative, and The Best of Jonathan Clements Book
Shining a light on the caregiving journey for lung cancer patients, Dr. Allison Applebaum, founder of the Caregiver's Clinic at Memorial Sloan Kettering Cancer Center, and caregiver Gail Fackler, along with her husband, Jim, speak candidly about the mental health challenges caregivers face, including anxiety, depression, and PTSD. The conversation covers the overwhelming realities of caregiving, from managing medical decisions to coping with guilt and loss of identity. Gail and Jim share raw, honest stories about how caregiving has transformed their lives and relationships. Practical strategies for caregivers—such as task management, setting boundaries, and finding support networks—offer hope and guidance. Learn more about the critical importance of mental health support for caregivers and the power of community in navigating this journey. Guests Dr. Allison Applebaum, Founding Director, Caregiver's Clinic, Memorial Sloan Kettering Cancer Center Gail and Jim Fackler, Lung Cancer Caregivers and Patient Show Notes | Transcript | Watch Video
In this episode, Jonathan Sackier kicks off a special miniseries on lung cancer with Haval Balata, Consultant Respiratory Physician at Manchester University NHS Foundation Trust. From the Manchester Lung Health Check to robotic bronchoscopy, Balata shares insights into pioneering early detection efforts, the challenge of public misconceptions, and innovations reshaping lung cancer screening and diagnosis. Timestamps: 03:12 – Inspiration to specialise 04:09 – Early diagnosis barriers 08:02 – Manchester Lung Health Check 14:10 – Robot-assisted bronchoscopy 19:24 – Public misconceptions 28:57 – Risk stratification & follow-up 34:24 – Innovations in early detection 37:10 – Hopes for the future 41:22 – Three healthcare wishes
In this deeply inspiring follow-up conversation, Jay Jay shares the life-changing role that cannabis has played in her journey, including her unexpected recovery from severe pain, a recurrence of brain tumors, and even a broken vertebrae from a seizure. She also speaks candidly about addiction, emotional healing, diet changes, and the power of education. Now working as Executive Director of EduCanNation, Jay Jay is paying it forward by helping others navigate their healing paths with cannabis and community.00:37 – Introduction: Jay Jay's return, 5+ years post-terminal diagnosis01:22 – Jay Jay's gratitude for the podcast and tribute to Corrie Yelland02:30 – Physical vs. emotional healing, addiction, and cannabis support03:44 – 10 months of undiagnosed pain before Jay Jay insisted it was cancer05:04 – Emotional toll of her prognosis and the loss of her mother06:11 – A fight for her life begins—rejection of the medical “death sentence”07:05 – No chemo, no radiation offered—turning to cannabis07:27 – The moment of clarity: watching Weed the People07:59 – Early cannabis oil experience: rookie mistake, fast pain relief09:20 – Daily dose now: 1.5 to 2 grams; feeling better than ever10:00 – A gene mutation leads to targeted therapy11:29 – Brain metastases return in 2023—11 tumors, then 8 more12:37 – Seizure leads to spinal fracture; cannabis helps her heal13:56 – Headaches and midline shift caused by brain tumors15:22 – Ian shares cannabis success stories for brain cancer15:58 – Jay Jay on life transformation—body, mind, and soul16:18 – Gaining new perspective after a “death sentence”17:07 – Her advice to those newly diagnosed: don't lose hope18:38 – The birth of EduCanNation and its founding story20:16 – Jay Jay's cannabis education journey and certifications21:11 – Cannabis skepticism vs. chemo acceptance—societal brainwashing22:39 – Helping others: a story about supporting her father-in-law24:25 – Emotional resilience and growth24:41 – Diet transformation—from vegetarian to carnivore27:07 – Honouring individual needs: no one-size-fits-all diet28:03 – Feeling healthier than ever despite diagnosis28:10 – How to contact Jay Jay and connect with EduCanNation Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover
LCC in Korean: Lung Cancer Updates & Future Directions by IASLC
In this episode, Dr. Paul Wheatley-Price chats with Dr. Dugald Seely, ND on naturopathic medicine and lung cancer - what is naturopathy vs alternative vs homeopathic medicine, how it can play a role within lung cancer care, the innovative research he's been doing, and busting some of the myths about CAM. Dr. Seely is a Naturopathic Doctor in Ottawa, CEO of the Center for Health Innovation, and Executive Director at the Patterson Institute for Integrative Oncology Research at the Canadian College of Naturopathic Medicine.
Today, Paul reflects on the work of Jonathan Clements, an author and former writer for The Wall Street Journal, who has not stopped trying to leave a legacy amid a terminal cancer diagnosis. Listen along as Paul explains why it is so important to have voices like these in the investing world and why the concept of market efficiency is the foundation that you build many other investing concepts on top of. For more information about what we do or how we can help you, schedule a 15-minute call with us here: paulwinkler.com/call.
Updated For 2025! This Week In Wrestling History (Season 3 Week 20) covering the period of 5/14 thru 5/20. Running Time: 4 Hours 10 Minutes. This Week In Wrestling History hosted by Don Tony first aired in 2018 and spanned two seasons. After much demand, these retro episodes return REMASTERED and UPDATED FOR 2025. Wrestling history up to and including 2024 has been added! Hundreds of hours of original wrestling clips & stories. Enjoy this deep dive into pro wrestling's awesome history. RUNNING TIME: 4 Hours 10 MinutesHosted by Don Tony SYNOPSIS: S3 E20 (05/14 - 05/20) The era of Bruno begins: Bruno Sammartino def Buddy Rogers to win WWWF Championship. Andy Kaufman passes away from Lung Cancer at 35 years old. Audio: AWA fu**ery: Playboy Buddy Rose & Doug Somers win the AWA Tag Team titles on a count out (from Scott Hall and Curt Hennig). Looking back at WCW Capital Combat: The Return Of Robocop (1990). Looking back at WCW SuperBrawl (1991). Audio: Sid Vicious vs El Gigante: Stretcher Match Looking back at WCW WarGames (1992). Papa Shango places a voodoo curse on a vomiting Ultimate Warrior, and the feud begins. AAA Promotion makes its debut (1992). Audio: The biggest upset in Raw histoy? The Kid def Razor Ramon. Audio: Marty Janetty makes WWF return and def Shawn Michaels for IC Championship. 'A Current Affair' episode debuts profiling the tragedies surrounding the Von Erich family. Looking back at ECW: When Worlds Collide (1994). Audio: Arn Anderson speaks on his one match in ECW and why it sucked. Looking back at AAA Triplemania II-B event (1994). WWF makes significant changes in drug policy in an attempt to prevent abuse. Looking back at the first ever WWF In Your House PPV (1995). Audio: Bob Backlund announces his candidacy for President and makes some comical errors at some historical events. Infamous Cliq Curtain Call takes place at Madison Square Garden. Audio: Triple H, Jim Cornette, Scott Hall, and Kevin Nash speak on the infamous MSG Curtain Call. Looking back at WCW Slamboree (1996, 1997, 1998). HBK infamous 'Sunny Days' Promo on Bret Hart airs on Raw. Audio: Sean Waltman reveals a 'Sunny Day' story involving Shawn Michaels. People Magazine wasn't the only fools running high profile Internet Polls in 1998. Looking back when Ric Flair had led Time Magazine's 'Person Of The Century' Poll. Looking back at ECW 'It Ain't Seinfeld' event (1998). Taz debuts the FTW (F*** The World) Championship. Audio: Eric Bischoff taunts Vince McMahon on WCW Thunder. Audio: Chris Jericho's introduces the participants in the Cruiserweight Battle Royal at Slamboree 1998. Audio: The night Dean Malenko received one of the loudest pops in WCW history. Referee Charles Robinson suffers collapsed lung after taking an elbow drop by Macho Man Randy Savage. Looking back at WCW No Mercy UK PPV (1999). Looking back at ECW Hardcore Heaven PPV (1999, 2000). Audio: Godfather's Ho (Bobcat) wins WWF Hardcore Title from Crash Holly. Audio: Don Tony's favorite WWF Hardcore Title match: Gerald Brisco vs Crash Holly. Looking back at WWE Judgement Day PPV (2000, 2001, 2002, 2003, 2004, 2007, 2008, 2009). Vince McMahon makes return appearance on HBO's 'On The Record with Bob Costas'. Zach Gowan makes WWF TV debut - by having his prosthetic leg yanked off by Rowdy Roddy Piper. Ron 'The Truth' Killings wins NWA World Heavyweight Championship for the 2nd time. Mordecai makes WWE main roster debut. Audio: Bobby Heenan on The Dennis Miller Show. TNA suspends Jeff Hardy. Looking back at TNA Hard Justice PPV (2005). Tickets for ECW One Night Stand go on sale and immediately sells out. Looking back at TNA Sacrifice PPV (2006, 2010). 'See No Evil' starring Kane hits movie theatres. WWE releases Sabu, Shelly Martinez, Scotty 2 Hotty, Nick Mitchell, Carlito and Angel Williams (Angelina Love). Audio: Bret Hart defeats The Miz to win the WWE US Championship. Hulk Hogan sues Fruity Pebbles Cereal (Post). Audio: TNA rebrands as 'Impact Wrestling' and 'Wrestling Matters'. TNA signs Brooke Hogan. Looking back at WWE Over The Limit PPV (2012). Looking back at WWE Extreme Rules PPV (2013). Audio: Kevin Owens makes WWE main roster debut. Looking back at NXT TakeOver: Unstoppable (2015). Samoa Joe makes NXT debut. Looking back at WWE Payback PPV (2015). Destination American announces cancellation of TNA Programming effective September 2015. Audio: New Day 'Time Machine' skit poking fun at The Vaudvillains Looking back at NXT TakeOver: Chicago (2017) WWE signs Io Sky (Io Shirai) WWE and FOX agree on a five-year deal to air SmackDown on Fox beginning in 2019 Charges dropped in the sexual assault case against Enzo Amore Ashley Massaro tragically passes away at 39 Audio: Mick Foley introduces WWE 24/7 Championship on RAW to a less than stellar response from live audience and IWC Looking back at WWE Money In The Bank 2019 Audio: Brock Lesnar makes surprise return, screws Mustafa Ali and wins MITB Briefcase Audio: Mustafa Ali reveals how everything went down behind the scenes at MITB and Brock Lesnar return Audio: Firefly Fun House takes a very dark turn as Bray Wyatt introduces us to The Fiend Audio: Shad Gaspard tragically passes away at 39 (news coverage) D-Von Dudley retires from in-ring competition Audio: Jim Cornette stirs up controversy discussing Becky Lynch pregnancy Looking back at WWE Backlash 2021 Looking back at Impact Wrestling: Under Siege 2021 Alexander Wolfe is kicked out of Imperium AND WWE in the same week WWE releases eight including Velveteen Dream, Alexander Wolfe, Jessamyn Duke, Adnan Virk and Drake Wuertz WBD announces new AEW: Rampage TV series coming to TNT Sasha Banks and Naomi quit WWE Audio: Michael Cole on air reaction to Sasha Banks and Naomi quitting WWE Stephanie McMahon announces an abrupt leave of absence from WWE Audio: RK-Bro (RAW Tag Champions) vs The Usos (SmackDown Tag Champions) battle in a Tag Team Unification Match Audio: Max Dupri makes his WWE TV debut WBD announces new AEW: Collision TV series coming to TNT AEW announces the creation of a new YouTube series: "Meal And A Match" Ruby Soho and Angelo Parker get married Mark Henry leaves AEW Audio: The beginning of the end of Ricky Starks in AEW. Ricky Starks expresses frustration over not being used and media pushing injuries as the excuse And so much more! RIGHT CLICK AND SAVE to download the AUDIO episode of THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) CLICK HERE to listen to COMMERCIAL FREE (PATREON) episode of THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) CLICK HERE to listen to THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) online CLICK HERE to access previous episodes for all the shows ==== CELEBRATE 20 YEARS OF DON TONY AND KEVIN CASTLE WITH THE DTKC 20 YEAR ANNIVERSARY SHIRT! CLICK HERE for DTKC Pro Wrestling Tees Store ==== Want to help promote our shows and get a special shout-out on the next show? Stop by Apple Podcasts (CLICK HERE) or SPOTIFY (CLICK HERE) and leave a review! Join Don Tony And Kevin Castle Show Patreon Family, and get a special shout-out on the next show! CLICK HERE ==== DON TONY AND KEVIN CASTLE *PATREON* AND *YOUTUBE CHANNEL MEMBERSHIPS: You can send additional support for Don Tony And Kevin Castle and help grow and keep the brand alive, by becoming a member of DT/KC PATREON and/or YOUTUBE CHANNEL MEMBERSHIP FAMILY. Don Tony and Kevin Castle's PATREON has been around for over seven years! You can access all eight years of BONUS CONTENT right now including: Ad-Free episodes of all of the weekly Non-Patreon shows Retro episodes of The Don Tony And Kevin Castle Show going back as early as 2004 (Retro Episodes added each week!) Weekly Patreon podcasts hosted by Don Tony Kevin Castle's entire library of Patreon exclusive shows. 2000+ hours of Patreon exclusive shows never released publicly! (Over 8 Years of Patreon Exclusive Content!) CLICK HERE to access DT/KC Patreon now! YOUTUBE CHANNEL MEMBERSHIPS: Another option is to become a CHANNEL MEMBER on YouTube. Get exclusive enhanced versions of weekly shows, access to DT's weekly Patreon show, retro DTKC Show episodes, giveaways and more. CLICK HERE for more details and to join The DT/KC YouTube Channel Member Family! ==== CHECK OUT OUR CONTENT ACROSS THESE PLATFORMS: CLICK HERE FOR APPLE PODCASTS CLICK HERE FOR SPOTIFY CLICK HERE FOR ANDROID CLICK HERE FOR AMAZON MUSIC CLICK HERE FOR GOOGLE PODCASTS CLICK HERE FOR PANDORA CLICK HERE FOR PODBEAN CLICK HERE FOR IHEARTRADIO CLICK HERE FOR DON TONY AND KEVIN CASTLE SHOW MERCHANDISE! ==== WEEKLY SHOW SCHEDULE (UPDATED: JANUARY 2025): WWE RAW RECAP AND WRESTLING NEWS REPORT: LIVE EVERY MONDAY NIGHT at 10:45PM ET after WWE RAW on DTKCDiscord.com DT VIPATREON: Patreon Exclusive Show hosted by Don Tony LIVE EVERY TUESDAY at 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every WEDNESDAY morning at DonTony.com (and across all audio platforms) THIS WEEK IN WRESTLING HISTORY: Posted every THURSDAY at DonTony.com (and across all audio platforms) CASTLE/KNT CHRONICLES: Patreon Exclusive Show hosted by Kevin Castle and Trez LIVE EVERY THURSDAY 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every FRIDAY morning at DonTony.com (and across all audio platforms) PRO WRESTLING WEEKEND NEWS UPDATE: Posted every SATURDAY at DonTony.com (and across all audio platforms) THE SIT-DOWN w/DON TONY: VIDEO PODCAST hosted by Don Tony LIVE EVERY SUNDAY at 8PM on YouTube (www.YouTube.com/DonTony) WWE/AEW PPV RECAP/REVIEW: (Posted MONDAY NIGHT as part of Don Tony and Kevin Castle Show) ==== SOCIAL MEDIA / WEBSITE / CONTACT INFO: Twitter: https://twitter.com/dontonyd Patreon: https://www.patreon.com/dontony Facebook: https://facebook.com/DTKCShow YouTube: https://www.youtube.com/dontony Website: https://www.wrestling-news.com
The latest podcast episode of Veteran Oversight Now highlights the VA OIG's oversight work during April 2025, including three healthcare facility inspections reports on facilities in Tennessee, New York, and Colorado. April 2025 Monthly HighlightsEach month, the VA Office of Inspector General publishes highlights of our congressional testimony, investigative work, and oversight reports. In April 2025, the VA OIG published 12 reports that included 51 recommendations. Report topics varied from a review to determine whether claims processors are properly assigning effective dates for PACT Act-related claims to an inspection related to a patient's delayed diagnosis and treatment for lung cancer at the VA Eastern Kansas Healthcare System in Topeka and Leavenworth. VA OIG investigative efforts helped resolved allegations that a drug and alcohol rehabilitation facility, Seabrook House in New Jersey, submitted claims to VA's Community Care program and the state's Medicaid program for short-term residential treatment and partial hospitalization care for which it was not properly licensed or contracted and misled state inspectors. In a civil settlement, Seabrook agreed to pay $19.75 million to resolve False Claims Act allegations. Of this amount, VA will receive $19.15 million. Meanwhile, 12 employees of the Louis Stokes Cleveland VA Medical Center pleaded guilty to theft after receiving more than $396,000 in Pandemic Unemployment Assistance benefits by falsifying their applications and failing to disclose their employment and wages earned at VA, and a physician at the Bedford VA Medical Center in Massachusetts was arrested and charged in the District of Massachusetts with the receipt and possession of child pornography.Read the full monthly highlights. Related Reports:The PACT Act Has Complicated Determining When Veterans' Benefits Payments Should Take EffectDelayed Diagnosis and Treatment for a Patient's Lung Cancer and Deficiencies in the Lung Cancer Screening Program at the VA Eastern Kansas Healthcare System in Topeka and LeavenworthHiring of Claims Processors Generally Met Requirements and the Attrition Rate Remained Steady
See if you can follow along and recall this underrated comic book adaptation as well as Michael did!
Mikayla Pittman, Manager of Nationwide Lung Cancer Screening for the American Lung Association, joins Lisa Dent to discuss the rise of lung cancer in those who have never smoked.
Program notes:0:47 Gun injuries and deer hunting season1:47 Other associated injuries2:47 Coincidence of hunting?3:48 Restrict hunting guns to that use4:10 Can we avoid surgery in some with cancer?5:10 Dostarlimab treatment6:10 Can help avoid surgery in few who have this mutation7:10 Look at specific pathways7:30 Lung cancer treatment8:32 71% responded9:12 Impact of Pepfar funding freeze10:12 Looked at waiver scenarios11:12 Decreased deaths and infection12:13 Takes time to resume13:06 End
Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode, Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives. Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.
Arthur Robin Williams is an associate professor of clinical psychiatry at Columbia University and a research scientist at the New York State Psychiatric Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.R. Williams. Death and Taxes — Is Alcohol the Solution? N Engl J Med 2025;392:1665-1667.
In this episode, you'll hear about the latest developments in tailoring cancer treatments to individual patients using Precision Oncology. Two thought leaders, Simone Ndujiuba, a Clinical Oncology Pharmacist at Prime Therapeutics, and Karan Cushman, Head of Brand Experience and host of The Precision Medicine Podcast for Trapelo Health, discuss real-world research that is paving the way for Prime and our partners to help providers reduce turnaround times so patients can start treatment as soon as possible. Join your host Maryam Tabatabai as they dig into this evolving topic of precision oncology. www.primetherapeuitics.com ChaptersDefining precision medicine (08:50)Evaluating real-world operational process of biomarker testing (14:36)Turnaround times are crucial (17:40)A patients view into the importance of time (24:39)Technology and process aid in time and process (29:30)Helping bridge knowledge gaps for providers and payers (33:55) The focus is on Precision Oncology right now (37:00)Precision medicine in other disease categories (40:09)Future of precision oncology is bright (42:07) References Singh, B.P., et al. (2019). Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). American Society of Clinical Oncology. https://meetings. asco.org/abstracts-presentations/173392 Evangelist, M.C., et al. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41(Supplement 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.9109. Ossowski, S., et al. (2022). Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small cell lung cancer. Journal of Clinical Oncology, 18(11). https://doi.org/10.1200/OP.22.00260 Naithani N, Atal AT, Tilak TVSVGK, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021 Jul;77(3):258-265. doi: 10.1016/j.mjafi.2021.06.020. Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019 Jul;24(7):e432-e440. doi: 10.1634/theoncologist.2019-0054. MedlinePlus. What is genetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/genetics/understanding/testing/genetictesting/. MedlinePlus. What is pharmacogenetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetics%20(also%20called%20pharmacogenomics)%20is,your%20height%20and%20eye%20color. Riely GJ, Wood DE, Aisner DL, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: non-small cell lung cancer, V3.2005. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Benson AB, Venook AP, Adam M, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: colon cancer, V3.2025. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Rosenberg PS, Miranda-Filho A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw Open. 2024 Jun 3;7(6):e2415731. doi: 10.1001/jamanetworkopen.2024.15731. PMID: 38857048; PMCID: PMC11165384. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002.The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice.
Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]
In this special re-release of Hope With Answers, lung cancer advocate Jill Feldman tackles a challenge that most patients never see coming—stigma. Originally aired in January 2020, this candid and emotional episode sheds light on the damaging assumptions patients face and how words can wound, even when well-intentioned. From doctors and friends to complete strangers, the first question many patients hear is: “Did you smoke?” It's a question that implies blame—and lung cancer survivors like Jill Feldman have heard it far too often. In this episode, Jill teams up with journalist Steven Petrow to unpack the emotional toll of these encounters and offer advice on how to respond with grace and strength. You'll also hear from Dr. Alice Berger, a lung cancer researcher investigating why young, non-smoking women are increasingly being diagnosed with lung cancer. Her work helps shift public perception and challenges outdated assumptions about who gets lung cancer—and why. This episode explores: The real impact of stigma on lung cancer patients How language shapes the patient experience What not to say to someone with lung cancer How empathy and civility can reshape conversations Groundbreaking research on lung cancer in non-smokers Whether you're a patient, caregiver, or advocate, this episode will change the way you think—and talk—about lung cancer. Show Notes | Transcript | Watch Video
Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]
Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]
In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai's innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.
Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients. In this episode, we covered: • The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers. • The complexities of biomarker testing, including NGS, IHC, and FISH amplification. • Patient characteristics and phenotypes associated with HER2-positive disease. • The current testing workflows in clinical practice and the role of liquid biopsies. • Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment. YouTube: https://youtu.be/gMi-sflQyQo Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!
Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't." "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI reveal-dx.com Download the transcript here
Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't." "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI reveal-dx.com Listen to the podcast here
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025. We dived into several key studies that are shaping the future of lung cancer treatment, including: • KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC). • LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy. • MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC. • KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy. Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies. YouTube: https://youtu.be/akoXXAUEl_8 Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast
Could it be the SHOTS?We are pummeled with headlines about the horrors of chronic disease and cancers in America. Thanks to the MSM and #MAHA propaganda we are conditioned to believe it's due environmental contamination, genetic disorders and/or super scary deadly airborne viruses, among other things.But what if it is all connected to a century of mass vaccination?According to researcher Judyth Vary Baker, the SV-40 contamination of polio shots in the 1950's has set in motion a devastating course of death and chronic disease in America and the cover up has been one of the most sophisticated mass propaganda operations ever witnessed.Her story of participation in the first gain of function research in New Orleans in 1963 is a fascinating peak into where it all started and is critical in understanding how to stop the lies and misinformation to protect ourselves and our families.Tune in LIVE ——> https://rumble.com/v6ryhpj-part-2-live-exclusive-with-judyth-vary-baker..htmlWatch LIVE TODAY and follow the SJ Show on Rumble HERE: https://rumble.com/c/TheShannonJoyShowStart COOKING with toxin free ceramic!! The 100% toxin free P600 sizzle set is 55% OFF for the SJ audience!! Go to https://www.chefsfoundry.com/joy today to claim the limited time discount!Shannon's Top Headlines April 10, 2025:The Media Playbook for Measles Looks a Lot Like Its COVID Playbook — This Time, Kids Are the Pawns: https://childrenshealthdefense.org/defender/mary-holland-media-playbook-measles-covid-children-pawns/PREP Act Immunity Debunked By Ed Berkovich: https://sashalatypova.substack.com/cp/160881332IVERMECTIN and FENBENDAZOLE TESTIMONIAL - 60s year old Nebraska woman with Stage 4 Lung Cancer was saved from Hospice after only 1 month: https://makismd.substack.com/p/ivermectin-and-fenbendazole-testimonial-9acWhat Happens After A Vaccine Injury? https://substack.com/home/post/p-159017762BREAKING NEWS: Japanese researchers discover COVID-19 mRNA Vaccine spike protein damages blood vessels for up to 17 months: https://makismd.substack.com/p/breaking-news-japanese-researchersSJ Show Notes:Please support Shannon's independent network with your donation HERE:https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVT6Support Our Sponsors:Please help us welcome an AMAZING new sponsor Blackout Coffee!! Here is a GREAT deal just for the Joy audience - 20% off your first order—just head to https://www.blackoutcoffee.com/?p=Y7GEtILQS and use code JOY at checkout.SJ Collagen SPECIAL DEAL!! Get your Native Path collagen 45% OFF with a stock up special for the SJ audience! www.getnativepathcollagen.com/joyBe ready before you need it! Stock up now and protect your family. Go to https://www.allfamilypharmacy.com/JOY and use code JOY10 for 10% off your order.Colonial Metals Group is the company Shannon trusts for all her metals purchases! Set up a SAFE & Secure IRA or 401k with a company who shares your values! Learn more HERE: https://colonialmetalsgroup.com/joyLightly prepped and READY to go. Always be prepared for ANY emergency with The Satellite Phone Store! Everything you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/JoyPlease consider Dom Pullano of PCM & Associates! He has been Shannon's advisor for over a decade and would love to help you grow!Call his toll free number today: 1-800-536-1368Or visit his website at https://www.pcmpullano.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Nature writer Andrew Darby on what he learned from his rambles through the wilds of Tasmania, communing with the world's oldest surviving trees. In particular, his ‘buttock clenching' ascent up a 60-metre-tall eucalyptus known as The Vibe Tower.Nature writer, Andrew Darby spent more than 20 years as a Fairfax correspondent based in Tasmania.His stories involved the natural beauty of the bush, including visits to wild places and to the people who protect them, but it was deadline-driven and he couldn't spend the time he wanted to.In 2017 Andrew was diagnosed with stage four lung cancer.He underwent immunotherapy and was given a maximum 18-months to live. It has been eight years since he entered his “second life”.Andrew was determined to fully inhabit his beloved Tasmanian bush, so he went by himself to commune with ancient trees.These are some of the world's oldest surviving trees, like King's Lomatia; some of the biggest trees, like a 60-metre-tall eucalyptus known as The Vibe Tower; and Andrew's favourite, the dignified Pencil Pine.The Ancients: Discovering the world's oldest surviving trees in wild Tasmania is published by Allen & Unwin.This episode of Conversations touches on wild Tasmania, ancient trees, Pencil Pine, King's Lomatia, King Billy Pine, Giant Eucalyptus, Peter Dombrovskis photography, Walls of Jerusalem National Park, Pool of Siloam, epic hike, solo hike, stage four lung cancer, immunotherapy, second life and loving nature, hikes of Australia.
Anxiety is the most common mental disorder in the United States – even more common than depression!!! And don't miss the following topics that Terry will also discuss on this show: Lung Cancer in “Never Smoked” People is Increasing Dry Eye Problems Spike in the Winter Stressed at Work? Try Red Ginseng! What's In Your Water? Test Your Knowledge: Health Trivia Questions Vitamin D and Dementia Prevention Effects of Long COVID on Exercise
Welcome back to this week's Friday Review where I can't wait to share with you the best of the week! I'm looking forward to reviewing: Puriya Skin Repair Foot Balm (product review) The Healthiest Toothpastes (product review) Lung Cancer & RX (research) Accurate Blood Pressure Reading (research) For all the details tune into this week's Cabral Concept 3346 – Enjoy the show and let me know what you thought! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3346 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Drs. Sabari and Yu discuss the molecular landscape of HER2-mutant lung cancer, including its genomic characteristics, common co-mutations, and differences between HER2 mutations and HER2 amplification. This discussion also explores the prevalence and clinical patterns of HER2 mutations, their oncogenic mechanisms, their impact on tumor behavior and metastases, and potential environmental or genetic contributors to their development.
Helena Yu, MD and Joshua Sabari, MD explore the importance of testing for HER2 alterations in lung cancer; how HER2 positivity influences clinical decision-making; and the key methods used for detection, including immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. It also addresses challenges in standardizing HER2 testing, disparities in access to biomarker testing, and the evolving role of liquid biopsy compared to traditional tissue biopsy.